Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 491 results for %s

  1. User guide for the cost comparison company evidence submission template (PMG32)

    This user guide describes how to submit evidence to NICE when a cost-comparison case is made as part of the fast track technology appraisal process. It explains what information NICE requires and the format in which it should be presented

  2. Pneumonia: diagnosis and management (NG250)

    This guideline covers diagnosing, assessing, and treating community-acquired and hospital-acquired pneumonia, including bacterial pneumonia secondary to COVID-19, in babies over 1 month (corrected gestational age), children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.

  3. Depression in adults with a chronic physical health problem: recognition and management (CG91)

    This guideline covers identifying, treating and managing depression in people aged 18 and over who also have a chronic physical health problem such as cancer, heart disease or diabetes. It aims to improve the care of people with a long-term physical health problem, which can cause or exacerbate depression. This has the potential to increase their quality of life and life expectancy.

  4. Guide to the technology appraisal and highly specialised technologies appeal process (pre June 2023) (PMG18)

    This document concerns the appeal process for the technology appraisal and highly specialised technologies programmes and provides an overview for organisations wishing to lodge an appeal

  5. Guide to the technology appraisal and highly specialised technologies appeal process (PMG41)

    This guide outlines the appeal process for the technology appraisal and highly specialised technologies guidance. It sets out the process that NICE follows for appeals and provides guidance for those who wish to make an appeal or who are considering doing so

  6. Social anxiety disorder: recognition, assessment and treatment (CG159)

    This guideline covers recognising, assessing and treating social anxiety disorder (also known as ‘social phobia’) in children and young people (from school age to 17 years) and adults (aged 18 years and older). It aims to improve symptoms, educational, occupational and social functioning, and quality of life in people with social anxiety disorder.

  7. Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections (ES39)

    Summary of the evidence on oritavancin for acute bacterial skin and skin structure infections (ABSSSI) in adults

  8. Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer (TA61)

    Evidence-based recommendations on capecitabine for treating metastatic colorectal cancer in adults.

  9. Schizophrenia: lurasidone (ESNM48)

    Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making

  10. What pathophysiological mechanism(s) underlie the most common presentations of post-COVID-19 syndrome? For example, generalised fatigue, breathlessness, and “brain fog”?

    Recommendation ID NG188/6 Question What pathophysiological mechanism(s) underlie the most common presentations of post-COVID-19...

  11. Purchasing steps: further competition

    mini competition can be used to appoint: a supplier for a specific resource(s), or to select a supplier for a resource type for a set...

  12. What is the clinical and cost effectiveness of fitting amplification devices(s) in people with tinnitus who have hearing loss but no perceived hearing difficulties?

    What is the clinical and cost effectiveness of fitting amplification devices(s) in people with tinnitus who have hearing loss but no...

  13. Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (TA1019)

    Evidence-based recommendations on crovalimab (Piasky) for paroxysmal nocturnal haemoglobinuria in people 12 years and over.

  14. NICE encourages further research into single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) for treating morbid obesity, particularly research examining long-term outcomes. NICE may update the guidance on publication of further evidence.

    into single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) for treating morbid obesity, particularly research...

  15. Hyperhidrosis: oxybutynin (ES10)

    Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making